Search

Your search keyword '"Chong, Geoffrey"' showing total 145 results
Start Over Author "Chong, Geoffrey"
145 results on '"Chong, Geoffrey"'

1. Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Author

Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., and Salles, Gilles

Published
2024
Full Text
View/download PDF

3. Immune priming with avelumab and rituximab prior to R-CHOP in diffuse large B-cell lymphoma: the phase II AvR-CHOP study

Author

Manos, Kate, Chong, Geoffrey, Keane, Colm, Lee, Sze-Ting, Smith, Charmaine, Churilov, Leonid, McKendrick, Joseph, Renwick, William, Blombery, Piers, Burgess, Melinda, Nelson, Niles Elizabeth, Fancourt, Tineke, Hawking, Joanne, Lin, Wendi, Scott, Andrew M., Barraclough, Allison, Wight, Joel, Grigg, Andrew, Fong, Chun Yew, and Hawkes, Eliza A.

Published
2023
Full Text
View/download PDF

5. Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.

Author

Baggio, Diva, Chung, Eliza, Wellard, Cameron, Waters, Neil, Cushion, Tania, Chong, Geoffrey, Cochrane, Tara, Cull, Gavin, Giri, Pratyush, Hamad, Nada, Johnston, Anna, Lee, Denise, Murali, Aarya, Morgan, Susan, Mulligan, Stephen, Talaulikar, Dipti, Ratnasingam, Sumita, Wood, Erica, Hawkes, Eliza, and Opat, Stephen

Subjects
CHRONIC lymphocytic leukemia, RISK assessment, PROTEIN kinase inhibitors, PUBLIC health surveillance, RESEARCH funding, AGE distribution, REPORTING of diseases, DESCRIPTIVE statistics, CONFIDENCE intervals, SECONDARY primary cancer, PATIENT aftercare, PREVENTIVE health services, DISEASE risk factors, DISEASE complications
Abstract

Population‐based studies have demonstrated a high risk of second cancers, especially of the skin, among patients with chronic lymphocytic leukaemia (CLL). We describe age‐standardised incidence ratios (SIRs) of second primary malignancies (SPM) in Australian patients with relapsed/refractory CLL treated with at least two lines of therapy, including ibrutinib. From December 2014 to November 2017, 156 patients were identified from 13 sites enrolled in the Australasian Lymphoma and Related Diseases Registry, and 111 had follow‐up data on rates of SPM. At 38.4 months from ibrutinib therapy commencement, 25% experienced any SPM. SIR for melanoma and all cancers (excluding nonmelanomatous skin cancers) were 15.8 (95% confidence interval (CI): 7.0–35.3) and 4.6 (95% CI: 3.1–6.9) respectively. These data highlight the importance of primary preventive interventions and surveillance, particularly as survival from CLL continues to improve. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma

Author

Lenz, Georg, Hawkes, Eliza, Verhoef, Gregor, Haioun, Corinne, Thye Lim, Soon, Seog Heo, Dae, Ardeshna, Kirit, Chong, Geoffrey, Haaber, Jacob, Shi, Wei, Gorbatchevsky, Igor, Lippert, Susanne, Hiemeyer, Florian, Piraino, Paolo, Beckmann, Georg, Peña, Carol, Buvaylo, Viktoriya, Childs, Barrett H., and Salles, Gilles

Published
2020
Full Text
View/download PDF

9. Poor outcomes for trial‐ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B‐cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.

Author

Shaw, Briony, Chung, Eliza, Wellard, Cameron, Yoo, Edward, Bennett, Rory, Birks, Callum, Johnston, Anna, Cheah, Chan Y, Hamad, Nada, Simpson, Jock, Barraclough, Allison, Ku, Matthew, Viiala, Nicholas, Ratnasingam, Sumita, Armytage, Tasman, Cochrane, Tara, Chong, Geoffrey, Lee, Denise, Manos, Kate, and Keane, Colm

Published
2024
Full Text
View/download PDF

11. Supplementary Tables from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, primary, Savas, Peter, primary, Da Gama Duarte, Jessica, primary, Chong, Geoffrey, primary, Brown, Stephen, primary, Wong, Rachel, primary, Price, Timothy J., primary, Wann, Alysson, primary, Skrinos, Effie, primary, Mariadason, John M., primary, and Tebbutt, Niall C., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Legend from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, primary, Savas, Peter, primary, Da Gama Duarte, Jessica, primary, Chong, Geoffrey, primary, Brown, Stephen, primary, Wong, Rachel, primary, Price, Timothy J., primary, Wann, Alysson, primary, Skrinos, Effie, primary, Mariadason, John M., primary, and Tebbutt, Niall C., primary

Published
2023
Full Text
View/download PDF

13. Supp Figure 2 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, primary, Savas, Peter, primary, Da Gama Duarte, Jessica, primary, Chong, Geoffrey, primary, Brown, Stephen, primary, Wong, Rachel, primary, Price, Timothy J., primary, Wann, Alysson, primary, Skrinos, Effie, primary, Mariadason, John M., primary, and Tebbutt, Niall C., primary

Published
2023
Full Text
View/download PDF

14. Supp Figure 1 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, primary, Savas, Peter, primary, Da Gama Duarte, Jessica, primary, Chong, Geoffrey, primary, Brown, Stephen, primary, Wong, Rachel, primary, Price, Timothy J., primary, Wann, Alysson, primary, Skrinos, Effie, primary, Mariadason, John M., primary, and Tebbutt, Niall C., primary

Published
2023
Full Text
View/download PDF

15. Supp Figure 3 from Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, primary, Savas, Peter, primary, Da Gama Duarte, Jessica, primary, Chong, Geoffrey, primary, Brown, Stephen, primary, Wong, Rachel, primary, Price, Timothy J., primary, Wann, Alysson, primary, Skrinos, Effie, primary, Mariadason, John M., primary, and Tebbutt, Niall C., primary

Published
2023
Full Text
View/download PDF

16. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry

Author

Baggio, Diva, primary, Wellard, Cameron, additional, Chung, Eliza, additional, Talaulikar, Dipti, additional, Keane, Colm, additional, Opat, Stephen, additional, Giri, Pratyush, additional, Minson, Adrian, additional, Cheah, Chan Yoon, additional, Armytage, Tasman, additional, Lee, Denise, additional, Chong, Geoffrey, additional, Johnston, Anna, additional, Cochrane, Tara, additional, Waters, Neil, additional, Hamad, Nada, additional, Wood, Erica M., additional, Hawkes, Eliza A., additional, Balendra, John, additional, Barraclough, Allison, additional, Berkahn, Leanne, additional, Bosco, Annmarie, additional, Carradice, Duncan, additional, Chuah, Hun, additional, Coyle, Luke, additional, Crassini, Kyle, additional, Kenealy, Melita, additional, Ku, Matthew, additional, Leung, Teresa, additional, Manos, Kate, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Palfreymen, Emma, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Simpson, Jock, additional, Trotman, Judith, additional, Viiala, Nicholas, additional, and Wight, Joel, additional

Published
2022
Full Text
View/download PDF

17. Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.

Author

Baggio, Diva, Wellard, Cameron, Chung, Eliza, Talaulikar, Dipti, Keane, Colm, Opat, Stephen, Giri, Pratyush, Minson, Adrian, Cheah, Chan Yoon, Armytage, Tasman, Lee, Denise, Chong, Geoffrey, Johnston, Anna, Cochrane, Tara, Waters, Neil, Hamad, Nada, Wood, Erica M., Hawkes, Eliza A., Balendra Dr, John, and Barraclough Dr, Allison

Subjects
MANTLE cell lymphoma, BRUTON tyrosine kinase, MEDICAL registries, PATIENTS' attitudes, LYMPHOMAS
Abstract

Bruton's tyrosine kinase inhibitors (BTKi) have an established role in the management of patients with relapsed/refractory mantle cell lymphoma (MCL). However, scant data exist on outcomes of patients ineligible for clinical trials testing these therapies. We describe a contemporary cohort of relapsed/refractory MCL patients from the Australasian Lymphoma and Related Diseases Registry treated with ibrutinib December 2014 until July 2018, to determine the proportion potentially eligible for original trials, reasons for ineligibility and survival outcomes. Of 44 patients, 41% met one or more exclusion criteria from previous phase II/III MCL BTKi studies. Median progression-free and overall survival were 13.7 months (95% CI 6.2–28.1) and 15.6 months (95% CI 10.8–29.6) respectively and were shorter in patients excluded from clinical trials based on ECOG ≥2. Ibrutinib has demonstrable clinical effectiveness in a population enriched for unfit and trial-ineligible patients, and a need for more inclusive enrollment criteria in future BTKi studies is highlighted. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

18. Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry

Author

Wood, Erica, primary, Anderson, Mary-Ann, additional, Berkahn, Leanne, additional, Cheah, Chan, additional, Dickinson, Michael, additional, Gandhi, Maher, additional, Giri, Pratyush, additional, Hawkes, Eliza, additional, Johnston, Anna, additional, Keane, Colm, additional, McQuilten, Zoe, additional, Mulligan, Stephen, additional, Talaulikar, Dipti, additional, Opat, Stephen, additional, Trotman, Judith, additional, Williams, Janne, additional, Armytage, Tasman, additional, Barraclough, Allison, additional, Carradice, Duncan, additional, Chong, Geoffrey, additional, Cochrane, Tara, additional, Hamad, Nada, additional, Ku, Matthew, additional, Lee, Denise, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Wight, Joel, additional, Badoux, Xavier, additional, Cull, Gavin, additional, Kuss, Byrone, additional, Marlton, Paula, additional, Tam, Constantine, additional, Casan, Joshua, additional, Cushion, Tania, additional, Tedjaseputra, Aditya, additional, Birch, Simone, additional, Brown, Christina, additional, Ellis, David, additional, Harvey, Yasmin, additional, Hitchins, Sam, additional, Jain, Sanjiv, additional, Jessup, Peter, additional, Juneja, Surendar, additional, Kearney, Daniel, additional, Kumar, Beena, additional, Lade, Stephen, additional, Lee, Kenneth, additional, Leslie, Connull, additional, Long, Eileen, additional, Morey, Adrienne, additional, Nath, Lakshmi, additional, Norris, Debra, additional, Parker, Andrew, additional, Parry, Jeremy, additional, Chen, Fiona Pin-Yen, additional, Chung, Eliza, additional, Morison, Jessica, additional, Rowsell, Luke, additional, George, Gayathri St, additional, Thu, Christianto, additional, Waters, Neil, additional, Wellard, Cameron, additional, and Zheng, Michelle, additional

Published
2022
Full Text
View/download PDF

21. Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Author

Manos, Kate, primary, Khor, Richard, additional, Chong, Geoffrey, additional, Palmer, Jodie, additional, MacManus, Michael, additional, Keane, Colm, additional, Scott, Andrew M., additional, Shortt, Jake, additional, Ritchie, David, additional, Churilov, Leonid, additional, Johnston, Laura, additional, Witkowski, Tom, additional, Barraclough, Allison, additional, Lee, Sze Ting, additional, Lin, Wendi, additional, Koldej, Rachel, additional, and Hawkes, Eliza, additional

Published
2021
Full Text
View/download PDF

22. Additional file 1 of Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Author

Wang, Michael, Ramchandren, Radhakrishnan, Chen, Robert, Karlin, Lionel, Chong, Geoffrey, Jurczak, Wojciech, Wu, Ka Lung, Bishton, Mark, Collins, Graham P., Eliadis, Paul, Peyrade, Fr��d��ric, Lee, Yihua, Eckert, Karl, Neuenburg, Jutta K., and Tam, Constantine S.

Abstract

Additional file 1. SUPPLEMENTARY INFORMATION: Supplemental Methods; Table S1. Patient Disposition; Table S2. Safety Summary; Figure S1. SYMPATICO study schemas; Figure S2. Schema to determine randomized phase 3 dosing; Figure S3. Metabolic laboratory values and abnormalities in one patient with laboratory TLS; Supplementary Figure S4. Overall survival.

Published
2021
Full Text
View/download PDF

23. Maintenance of Moderate to High Levels of Functioning and Quality of Life with Odronextamab Monotherapy in Patients with Relapsed or Refractory Follicular Lymphoma

Author

Tessoulin, Benoit, Cho, Seok-Goo, Taszner, Michal, Kim, Tae Min, Novelli, Silvana, Villasboas, Jose C., Merli, Michele, Jimenez Ubieto, Ana, Poon, Michelle, Tucker, David, Walewski, Jan, Yi, Shuhua, Song, Yuqin, Chong, Geoffrey, Bachy, Emmanuel, Guidez, Stephanie, Alonso, Aranzazu, Jagadeesh, Deepa, Zhang, Wei, Magnano, Laura, Iskierka-Jazdzewska, Elzbieta, Tani, Monica, Cai, Jessica, Ivanescu, Cristina, Reaney, Matthew, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Harnett, James, Chi, Lei, and Luminari, Stefano

Published
2023
Full Text
View/download PDF

27. Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study

Author

Mooi, Jennifer, primary, Chionh, Fiona, additional, Savas, Peter, additional, Da Gama Duarte, Jessica, additional, Chong, Geoffrey, additional, Brown, Stephen, additional, Wong, Rachel, additional, Price, Timothy J., additional, Wann, Alysson, additional, Skrinos, Effie, additional, Mariadason, John M., additional, and Tebbutt, Niall C., additional

Published
2021
Full Text
View/download PDF

30. Safety and Efficacy of Induction and Maintenance Avelumab Plus R-CHOP in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Analysis of the Phase II Avr-CHOP Study

Author

Hawkes, Eliza A, primary, Chong, Geoffrey, additional, Smith, Charmaine, additional, Lee, Sze-Ting, additional, Churilov, Leonid, additional, McKendrick, Joseph, additional, Renwick, William, additional, Blombery, Piers, additional, Nelson, Niles Elizabeth, additional, Fancourt, Tineke, additional, Hawking, Joanne, additional, Lin, Wendi, additional, Scott, Andrew M, additional, Barraclough, Allison, additional, Wight, Joel, additional, Grigg, Andrew, additional, Keane, Colm, additional, Fong, Chun Yew, additional, and Manos, Kate, additional

Published
2020
Full Text
View/download PDF

31. Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study.

Author

Hawkes, Eliza Anne, primary, Manos, Kate, additional, Chong, Geoffrey, additional, Palmer, Jodie, additional, MacManus, Michael Patrick, additional, Keane, Colm, additional, Scott, Andrew Mark, additional, Shortt, Jake, additional, Ritchie, David, additional, Churilov, Leonid, additional, Johnston, Laura, additional, Witkowski, Tom, additional, Barraclough, Allison Anne, additional, Lee, Sze Ting, additional, Lin, Wendi, additional, Koldej, Rachel, additional, and Khor, Richard, additional

Published
2020
Full Text
View/download PDF

35. Specific Targeting, Biodistribution, and Lack of Immunogenicity of Chimeric Anti-GD3 Monoclonal Antibody KM871 in Patients With Metastatic Melanoma: Results of a Phase I Trial

Author

Scott, Andrew M., Lee, Fook-Thean, Hopkins, Wendie, Cebon, Jonathan S., Wheatley, Jennifer M., Liu, Zhanqi, Smyth, Fiona E., Murone, Carmel, Sturrock, Susan, MacGregor, Duncan, Hanai, Nobuo, Inoue, Kengo, Yamasaki, Motoo, Brechbiel, Martin W., Davis, Ian D., Murphy, Roger, Hannah, Anthony, Lim-Joon, Michael, Chan, Tony, Chong, Geoffrey, Ritter, Gerd, Hoffman, Eric W., Burgess, Antony W., and Old, Lloyd J.

Published
2001

36. Comprehensive geriatric assessment is useful in an elderly Australian population with diffuse large B‐cell lymphoma receiving rituximab‐chemotherapy combinations

Author

Ong, Doen Ming, primary, Ashby, Michael, additional, Grigg, Andrew, additional, Gard, Grace, additional, Ng, Zi Y., additional, Huang, Huayi (Ellen), additional, Chong, Yee Shuen, additional, Cheah, Chan Yoon, additional, Devitt, Bianca, additional, Chong, Geoffrey, additional, Loh, Zoe, additional, Mo, Allison, additional, and Hawkes, Eliza A., additional

Published
2019
Full Text
View/download PDF

37. Ability of routine blood tests (RBTs) in asymptomatic patients (pts) with indolent non-Hodgkin lymphoma (iNHL) to detect relapse or clinically significant disease progression.

Author

Piercey, Oliver, primary, Loh, Zoe, additional, Chan, Joanna, additional, Chong, Geoffrey, additional, Grigg, Andrew, additional, Cheema, Steven, additional, Cushion, Tania, additional, Gill, Gurjot, additional, Whybird, Matthew, additional, and Hawkes, Eliza Anne, additional

Published
2019
Full Text
View/download PDF

38. Patient selection and tolerability of high-dose methotrexate as central nervous system prophylaxis in diffuse large B-cell lymphoma.

Author

Garwood, Melissa J., Hawkes, Eliza A., Churilov, Leonid, and Chong, Geoffrey

Subjects
RITUXIMAB, PATIENT selection, CENTRAL nervous system, CD30 antigen, CEFAZOLIN, PREVENTIVE medicine, TEACHING hospitals, DRUG dosage, B cell lymphoma, CENTRAL nervous system tumors, ANTINEOPLASTIC agents, CANCER relapse, PROGNOSIS, RETROSPECTIVE studies, METHOTREXATE, ANTIMETABOLITES, DOSE-effect relationship in pharmacology, DRUG toxicity, LONGITUDINAL method
Abstract

Introduction: Central nervous system (CNS) relapse in diffuse large B-cell lymphoma (DLBCL) is usually fatal. Risk stratification of patients has historically been poorly defined, and CNS prophylaxis with high-dose methotrexate (HDMTX) can be associated with multiple toxicities. The CNS International Prognostic Index (IPI) defines three patient risk groups for CNS disease. The aims of this study were to evaluate the toxicity of HDMTX and describe outcomes in HDMTX and non-HDMTX patients according to the CNS-IPI.Methods: 205 patients diagnosed with DLBCL between 2004 and 2014, initially treated with RCHOP-like chemotherapy and considered for HDMTX CNS prophylaxis were identified by pharmacy records at two teaching hospitals. Patient records were retrospectively reviewed for HDMTX toxicity, CNS-IPI calculation and CNS relapse.Results: 28 patients with DLBCL were selected for two doses of HDMTX. Two of 28 patients received only one dose, and three had their second dose reduced due to renal impairment. 28% of patients experienced nephrotoxicity. 24 HDMTX and 122 non-HDMTX patients were evaluable for the CNS-IPI. No significant difference in the CNS-IPI distribution between the two groups was identified (p = 0.695). Five patients had CNS relapse, two who received HDMTX and three who did not. No significant difference in CNS relapse rate was identified between 24 HDMTX patients propensity-matched to 24 non-HDMTX patients.Conclusions: HDMTX was well-tolerated by patients. Application of the CNS-IPI identifies a different population of candidates for CNS prophylaxis compared to traditional criteria. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

41. Phase II study of single-agent copanlisib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Author

Lenz, Georg, primary, Hawkes, Eliza, additional, Verhoef, Gregor, additional, Haioun, Corinne, additional, Thye, Lim Soon, additional, Heo, Dae Seog, additional, Ardeshna, Kirit, additional, Chong, Geoffrey, additional, Christensen, Jacob Haaber, additional, Shi, Vivian, additional, Lippert, Susanne, additional, Hiemeyer, Florian, additional, Piraino, Paolo, additional, Pena, Carol Elaine, additional, Buvaylo, Viktoriya, additional, Childs, Barrett H., additional, Gorbatchevsky, Igor, additional, and Salles, Gilles A., additional

Published
2017
Full Text
View/download PDF

43. A randomized controlled trial of a nurse-led supportive care package (SurvivorCare) for survivors of colorectal cancer

Author

Jefford, Michael, Gough, Karla, Drosdowsky, Allison, Russell, Lahiru, Aranda, Sanchia, Butow, Phyllis, Phipps-Nelson, Jo, Young, Jane, Krishnasamy, Mei, Ugalde, Anna, King, Dorothy, Strickland, Andrew, Franco, Michael, Blum, Robert, Johnson, Catherine, Ganju, Vinod, Shapiro, Jeremy, Chong, Geoffrey, Charlton, Julie, Haydon, Andrew, Schofield, Penelope, Jefford, Michael, Gough, Karla, Drosdowsky, Allison, Russell, Lahiru, Aranda, Sanchia, Butow, Phyllis, Phipps-Nelson, Jo, Young, Jane, Krishnasamy, Mei, Ugalde, Anna, King, Dorothy, Strickland, Andrew, Franco, Michael, Blum, Robert, Johnson, Catherine, Ganju, Vinod, Shapiro, Jeremy, Chong, Geoffrey, Charlton, Julie, Haydon, Andrew, and Schofield, Penelope

Abstract

INTRODUCTION: Colorectal cancer (CRC) and its treatments can cause distressing sequelae. We conducted a multicenter randomized controlled trial aiming to improve psychological distress, supportive care needs (SCNs), and quality of life (QOL) of patients with CRC. The intervention, called SurvivorCare (SC), comprised educational materials, needs assessment, survivorship care plan, end-of-treatment session, and three follow-up telephone calls. METHODS: At the end of treatment for stage I-III CRC, eligible patients were randomized 1:1 to usual care (UC) or to UC plus SC. Distress (Brief Symptom Inventory 18), SCNs (Cancer Survivors' Unmet Needs measure), and QOL (European Organization for Research and Treatment of Cancer [EORTC] QOL questionnaires C30 and EORTC CRC module CR29) were assessed at baseline and at 2 and 6 months (follow-up 1 [FU1] and FU2, respectively). The primary hypothesis was that SC would have a beneficial effect on distress at FU1. The secondary hypotheses were that SC would have a beneficial effect on (a) SCN and QOL at FU1 and on (b) distress, SCNs, and QOL at FU2. A total of 15 items assessed experience of care. RESULTS: Of 221 patients randomly assigned, 4 were ineligible for the study and 1 was lost to FU, leaving 110 in the UC group and 106 in the SC group. Patients' characteristics included the following: median age, 64 years; men, 52%; colon cancer, 56%; rectal cancer, 35%; overlapping sites of disease, 10%; stage I disease, 7%; stage II, 22%; stage III, 71%. Baseline distress and QOL scores were similar to population norms. Between-group differences in distress at FU1 (primary outcome) and at FU2, and SCNs and QOL at FU1 and FU2 were small and nonsignificant. Patients in the SC group were more satisfied with survivorship care than those in the UC group (significant differences on 10 of 15 items). CONCLUSION: The addition of SC to UC did not have a beneficial effect on distress, SCNs, or QOL outcomes, but

Published
2016

44. A Randomized Controlled Trial of a Nurse-Led Supportive Care Package (SurvivorCare) for Survivors of Colorectal Cancer

Author

Jefford, Michael, primary, Gough, Karla, additional, Drosdowsky, Allison, additional, Russell, Lahiru, additional, Aranda, Sanchia, additional, Butow, Phyllis, additional, Phipps-Nelson, Jo, additional, Young, Jane, additional, Krishnasamy, Mei, additional, Ugalde, Anna, additional, King, Dorothy, additional, Strickland, Andrew, additional, Franco, Michael, additional, Blum, Robert, additional, Johnson, Catherine, additional, Ganju, Vinod, additional, Shapiro, Jeremy, additional, Chong, Geoffrey, additional, Charlton, Julie, additional, Haydon, Andrew, additional, and Schofield, Penelope, additional

Published
2016
Full Text
View/download PDF

45. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC).

Author

Jefford, Michael, primary, Gough, Karla, additional, Drosdowsky, Allison, additional, Russell, Lahiru, additional, Aranda, Sanchia, additional, Butow, Phyllis Noemi, additional, Phipps-Nelson, Jo, additional, Young, Jane, additional, Krishnasamy, Meinir, additional, Ugalde, Anna, additional, King, Dorothy, additional, Strickland, Andrew, additional, Franco, Michael Edward, additional, Blum, Robert helmut, additional, Johnson, Catherine, additional, Ganju, Vinod, additional, Shapiro, Jeremy, additional, Chong, Geoffrey, additional, Charlton, Julie, additional, and Schofield, Penelope, additional

Published
2016
Full Text
View/download PDF

47. Results of a Second, Prespecified Analysis of the Phase 2 Study ELM-2 Confirm High Rates of Durable Complete Response with Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) with Extended Follow-up

Author

Villasboas, Jose. C., Kim, Tae Min, Taszner, Michal, Novelli, Silvana, Cho, Seok-Goo, Merli, Michele, Jimenez Ubieto, Ana, Tessoulin, Benoit, Poon, Michelle, Walewski, Jan, Yi, Shuhua, Song, Yuqin, Chong, Geoffrey, Luminari, Stefano, Bachy, Emmanuel, Guidez, Stephanie, Alonso, Aranzazu, Jagadeesh, Deepa, Zhang, Wei, Magnano, Laura, Iskierka-Jażdżewska, Elżbieta, Tani, Monica, Cai, Jessica, Uppala, Amulya, Shariff, Saleem, Chi, Lei, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, and Tucker, David

Abstract

Background

Published
2023
Full Text
View/download PDF

48. Phase I Imaging and Pharmacodynamic Trial of CS-1008 in Patients With Metastatic Colorectal Cancer

Author

Ciprotti, Marika, primary, Tebbutt, Niall C., additional, Lee, Fook-Thean, additional, Lee, Sze-Ting, additional, Gan, Hui K., additional, McKee, David C., additional, O'Keefe, Graeme J., additional, Gong, Sylvia J., additional, Chong, Geoffrey, additional, Hopkins, Wendie, additional, Chappell, Bridget, additional, Scott, Fiona E., additional, Brechbiel, Martin W., additional, Tse, Archie N., additional, Jansen, Mendel, additional, Matsumura, Manabu, additional, Kotsuma, Masakatsu, additional, Watanabe, Rira, additional, Venhaus, Ralph, additional, Beckman, Robert A., additional, Greenberg, Jonathan, additional, and Scott, Andrew M., additional

Published
2015
Full Text
View/download PDF

49. A randomized controlled trial (RCT) of a supportive care package (SurvivorCare, SC) for survivors of colorectal cancer (CRC).

Author

Jefford, Michael, primary, Gough, Karla, additional, Drosdowsky, Allison, additional, Russell, Lahiru, additional, Aranda, Sanchia, additional, Butow, Phyllis Noemi, additional, Phipps-Nelson, Jo, additional, Young, Jane, additional, Krishnasamy, Meinir, additional, Ugalde, Anna, additional, King, Dorothy, additional, Strickland, Andrew, additional, Franco, Michael Edward, additional, Blum, Robert helmut, additional, Johnson, Catherine, additional, Ganju, Vinod, additional, Shapiro, Jeremy David, additional, Chong, Geoffrey, additional, Charlton, Julie, additional, and Schofield, Penelope, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results